Literature DB >> 25746053

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection.

Sandhya Vasan1, Supachai Rerks-Ngarm, Peter Gilbert, Barton Haynes, Sorachai Nitayapan, Punnee Pitisuttihum, Jaranit Kaewkungwal, Jean-Louis Excler, Merlin Robb, Nelson Michael, Jerome Kim, Robert O'Connell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25746053      PMCID： PMC4514177          DOI： 10.1080/21645515.2015.1010970

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  7 in total

1.  Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Authors:  Evgeny Shmelkov; Arthur Nadas; Timothy Cardozo
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

2.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

3.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

4.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Authors:  Merlin L Robb; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Patricia Morgan; Michael Benenson; Robert M Paris; Joseph Chiu; Elizabeth Adams; Donald Francis; Sanjay Gurunathan; Jim Tartaglia; Peter Gilbert; Don Stablein; Nelson L Michael; Jerome H Kim
Journal:  Lancet Infect Dis       Date:  2012-05-30       Impact factor: 25.071

5.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

6.  A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Authors:  Prasert Thongcharoen; Vinai Suriyanon; Robert M Paris; Chirasak Khamboonruang; Mark S de Souza; Silvia Ratto-Kim; Chitraporn Karnasuta; Victoria R Polonis; Lynn Baglyos; Raphaelle El Habib; Sanjay Gurunathan; Susan Barnett; Arthur E Brown; Deborah L Birx; John G McNeil; Jerome H Kim
Journal:  J Acquir Immune Defic Syndr       Date:  2007-09-01       Impact factor: 3.731

7.  Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.

Authors:  Georgia D Tomaras; Guido Ferrari; Xiaoying Shen; S Munir Alam; Hua-Xin Liao; Justin Pollara; Mattia Bonsignori; M Anthony Moody; Youyi Fong; Xi Chen; Brigid Poling; Cindo O Nicholson; Ruijun Zhang; Xiaozhi Lu; Robert Parks; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Peter B Gilbert; Jerome H Kim; Nelson L Michael; David C Montefiori; Barton F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-09       Impact factor: 11.205
  7 in total
  3 in total

Review 1.  Progress in HIV vaccine development.

Authors:  Denise C Hsu; Robert J O'Connell
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

Review 2.  Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization.

Authors:  Bin Su; Stefania Dispinseri; Valeria Iannone; Tong Zhang; Hao Wu; Raphael Carapito; Seiamak Bahram; Gabriella Scarlatti; Christiane Moog
Journal:  Front Immunol       Date:  2019-12-18       Impact factor: 7.561

Review 3.  Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV.

Authors:  Braira Wahid; Amjad Ali; Muhammad Idrees; Shazia Rafique
Journal:  Cell Immunol       Date:  2016-08-03       Impact factor: 4.868
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.